Published in World J Gastroenterol on December 21, 2009
Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: tumor budding as oncotarget. Oncotarget (2010) 1.88
The relationships between cellular components of the peritumoural inflammatory response, clinicopathological characteristics and survival in patients with primary operable colorectal cancer. Br J Cancer (2012) 1.31
Detailed analysis of inflammatory cell infiltration in colorectal cancer. Br J Cancer (2013) 1.30
Prognostic significance and molecular associations of tumor growth pattern in colorectal cancer. Ann Surg Oncol (2011) 1.16
The relationship between tumour stroma percentage, the tumour microenvironment and survival in patients with primary operable colorectal cancer. Ann Oncol (2014) 1.03
An improved image analysis method for cell counting lends credibility to the prognostic significance of T cells in colorectal cancer. Virchows Arch (2012) 0.96
Molecular and pathogenetic aspects of tumor budding in colorectal cancer. Front Med (Lausanne) (2015) 0.94
High tumour cannabinoid CB1 receptor immunoreactivity negatively impacts disease-specific survival in stage II microsatellite stable colorectal cancer. PLoS One (2011) 0.93
Cell surface markers in colorectal cancer prognosis. Int J Mol Sci (2010) 0.90
Prognostic value of innate and adaptive immunity in colorectal cancer. World J Gastroenterol (2013) 0.90
Overexpression of protein S100A4 is independently associated with overall survival in stage C colonic cancer but only in cytoplasm at the advancing tumour front. Int J Colorectal Dis (2012) 0.86
Lack of CD44 variant 6 expression in rectal cancer invasive front associates with early recurrence. World J Gastroenterol (2012) 0.86
Cathepsin D Expression in Colorectal Cancer: From Proteomic Discovery through Validation Using Western Blotting, Immunohistochemistry, and Tissue Microarrays. Int J Proteomics (2012) 0.85
Differential β-catenin expression levels are associated with morphological features and prognosis of colorectal cancer. Oncol Lett (2014) 0.84
Correlation between tumor budding and post-resection prognosis in patients with invasive squamous cell carcinoma of the thoracic esophagus. World J Surg (2011) 0.82
Invasion pattern and histologic features of tumor aggressiveness correlate with MMR protein expression, but are independent of activating KRAS and BRAF mutations in CRC. Virchows Arch (2014) 0.78
Digital microscopy assessment of angiogenesis in different breast cancer compartments. Biomed Res Int (2013) 0.77
A clinical model for predicting lymph node metastasis in submucosal invasive (T1) colorectal cancer. Int J Colorectal Dis (2015) 0.76
The expression and distribution of group IIA phospholipase A2 in human colorectal tumours. Virchows Arch (2010) 0.76
On the prognostic & predictive impact of immune cells system in colorectal cancer. Indian J Med Res (2012) 0.75
DAPK loss in colon cancer tumor buds: implications for migration capacity of disseminating tumor cells. Oncotarget (2015) 0.75
Accumulation of arachidonic acid-containing phosphatidylinositol at the outer edge of colorectal cancer. Sci Rep (2016) 0.75
Tumor budding as a potential histopathological biomarker in colorectal cancer: hype or hope? World J Gastroenterol (2012) 0.75
Identification of a characteristic vascular belt zone in human colorectal cancer. PLoS One (2017) 0.75
Matrix metalloproteases as maestros for the dual role of LPS- and IL-10-stimulated macrophages in cancer cell behaviour. BMC Cancer (2015) 0.75
Image analysis-derived metrics of histomorphological complexity predicts prognosis and treatment response in stage II-III colon cancer. Sci Rep (2016) 0.75
S100A8(+) stroma cells predict a good prognosis and inhibit aggressiveness in colorectal carcinoma. Oncoimmunology (2016) 0.75
Morphological Evaluation of Tumor-Infiltrating Lymphocytes (TILs) to Investigate Invasive Breast Cancer Immunogenicity, Reveal Lymphocytic Networks and Help Relapse Prediction: A Retrospective Study. Int J Mol Sci (2017) 0.75
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (2006) 24.54
Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med (2005) 12.64
Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst (2004) 10.61
Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc Natl Acad Sci U S A (2001) 7.99
Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology (2007) 7.16
American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol (2004) 7.16
CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res (1998) 6.42
Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol (2008) 6.01
Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med (2000) 5.68
Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences. Am J Pathol (1994) 4.43
The grading of rectal cancer: historical perspectives and a multivariate analysis of 447 cases. Histopathology (1986) 3.70
A new prognostic classification of rectal cancer. Lancet (1987) 3.56
Morphology of sporadic colorectal cancer with DNA replication errors. Gut (1998) 3.11
Prognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal cancer. J Pathol (1997) 3.09
Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue. Gut (2008) 2.97
Prognostic value of tumor "budding" in patients with colorectal cancer. Dis Colon Rectum (1993) 2.92
Histopathological identification of colon cancer with microsatellite instability. Am J Pathol (2001) 2.90
Tumor-infiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinoma. Cancer (2001) 2.82
Lymphocytic infiltration and survival in rectal cancer. J Clin Pathol (1986) 2.80
American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group. Cancer (2000) 2.80
Tumour 'budding' as an index to estimate the potential of aggressiveness in rectal cancer. Histopathology (2002) 2.68
Risk factors for an adverse outcome in early invasive colorectal carcinoma. Gastroenterology (2004) 2.66
The staging of colorectal cancer: 2004 and beyond. CA Cancer J Clin (2004) 2.65
Reduced likelihood of metastases in patients with microsatellite-unstable colorectal cancer. Clin Cancer Res (2007) 2.54
CD3+ cells at the invasive margin of deeply invading (pT3-T4) colorectal cancer and risk of post-surgical metastasis: a longitudinal study. Lancet Oncol (2009) 2.47
Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human colorectal cancer. Cancer Immun (2007) 2.44
Elevated preoperative neutrophil to lymphocyte ratio predicts survival following hepatic resection for colorectal liver metastases. Eur J Surg Oncol (2007) 2.42
Pathology features in Bethesda guidelines predict colorectal cancer microsatellite instability: a population-based study. Gastroenterology (2007) 2.39
Comparison of the prognostic value of inflammation-based pathologic and biochemical criteria in patients undergoing potentially curative resection for colorectal cancer. Ann Surg (2009) 2.22
Prognostic value of the CD4+/CD8+ ratio of tumour infiltrating lymphocytes in colorectal cancer and HLA-DR expression on tumour cells. Cancer Immunol Immunother (2003) 2.11
Mast cells are an essential hematopoietic component for polyp development. Proc Natl Acad Sci U S A (2007) 2.02
Phenotype of microsatellite unstable colorectal carcinomas: Well-differentiated and focally mucinous tumors and the absence of dirty necrosis correlate with microsatellite instability. Am J Surg Pathol (2003) 1.97
High frequency of tumor-infiltrating FOXP3(+) regulatory T cells predicts improved survival in mismatch repair-proficient colorectal cancer patients. Int J Cancer (2010) 1.96
Tumour budding in colorectal carcinoma. Histopathology (2007) 1.93
Prognostic role of CD8+ tumor-infiltrating lymphocytes in stage III colorectal cancer with and without microsatellite instability. Hum Pathol (2004) 1.89
Intraepithelial CD8+ T-cell-count becomes a prognostic factor after a longer follow-up period in human colorectal carcinoma: possible association with suppression of micrometastasis. Br J Cancer (2004) 1.80
MUC1 and nuclear beta-catenin are coexpressed at the invasion front of colorectal carcinomas and are both correlated with tumor prognosis. Clin Cancer Res (2004) 1.77
Gastrointestinal stem cells in development and cancer. J Pathol (2009) 1.73
The relationship between tumour T-lymphocyte infiltration, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer. Br J Cancer (2005) 1.69
Prognostic significance of CXCL12 expression in patients with colorectal carcinoma. Am J Clin Pathol (2009) 1.66
Tumor budding is a strong and reproducible prognostic marker in T3N0 colorectal cancer. Am J Surg Pathol (2009) 1.63
Sporadic colorectal adenocarcinomas with high-frequency microsatellite instability. Cancer (2000) 1.56
Value of histopathology in predicting microsatellite instability in hereditary nonpolyposis colorectal cancer and sporadic colorectal cancer. Am J Surg Pathol (2003) 1.54
Tumor dedifferentiation: an important step in tumor invasion. Clin Exp Metastasis (1986) 1.54
beta(III)-tubulin at the invasive margin of colorectal cancer: possible link to invasion. Virchows Arch (2009) 1.52
Epithelial-mesenchymal transition mediated tumourigenesis in the gastrointestinal tract. World J Gastroenterol (2008) 1.51
Tumour-infiltrating lymphocytes in colorectal cancer with microsatellite instability are activated and cytotoxic. Br J Surg (2004) 1.49
Evaluation of venous invasion by Elastica van Gieson stain and tumor budding predicts local and distant metastases in patients with T1 stage colorectal cancer. Am J Surg Pathol (2009) 1.46
Loss of membranous Ep-CAM in budding colorectal carcinoma cells. Mod Pathol (2007) 1.45
Colorectal cancers with microsatellite instability display mRNA expression signatures characteristic of increased immunogenicity. Mol Cancer (2004) 1.42
Prognostic value of tumor-infiltrating dendritic cells in colorectal cancer: role of maturation status and intratumoral localization. Clin Cancer Res (2005) 1.38
Prognostic significance of mast cell number and microvascular density for the survival of patients with primary colorectal cancer. J Gastroenterol Hepatol (2007) 1.37
Tumour budding as prognostic factor in stage I/II colorectal carcinoma. Histopathology (2005) 1.34
Tumor budding at the invasive margin can predict patients at high risk of recurrence after curative surgery for stage II, T3 colon cancer. Dis Colon Rectum (2003) 1.25
Role of APAF-1, E-cadherin and peritumoral lymphocytic infiltration in tumour budding in colorectal cancer. J Pathol (2007) 1.22
CD8+ lymphocytes/ tumour-budding index: an independent prognostic factor representing a 'pro-/anti-tumour' approach to tumour host interaction in colorectal cancer. Br J Cancer (2009) 1.21
Predictors of extrahepatic recurrence after resection of colorectal liver metastases. Br J Surg (2004) 1.20
T cell infiltrate predicts long-term survival following resection of colorectal cancer liver metastases. Ann Surg Oncol (2009) 1.20
Mature dendritic cells make clusters with T cells in the invasive margin of colorectal carcinoma. J Pathol (2002) 1.14
T-regulatory cell modulation: the future of cancer immunotherapy? Br J Cancer (2009) 1.13
Tumour T-lymphocyte subset infiltration and tumour recurrence following curative resection for colorectal cancer. Eur J Surg Oncol (2004) 1.12
Tumour budding at the deepest invasive margin correlates with lymph node metastasis in submucosal colorectal cancer detected by anticytokeratin antibody CAM5.2. Br J Cancer (2006) 1.11
Intensity of tumor budding and its prognostic implications in invasive colon carcinoma. Dis Colon Rectum (2005) 1.11
Differential significance of tumour infiltrating lymphocytes in sporadic mismatch repair deficient versus proficient colorectal cancers: a potential role for dysregulation of the transforming growth factor-beta pathway. Eur J Cancer (2007) 1.10
Dendritic cells in colorectal cancer correlate with other tumor-infiltrating immune cells. Cancer Immunol Immunother (2004) 1.08
Curative resection of T1 colorectal carcinoma: risk of lymph node metastasis and long-term prognosis. Dis Colon Rectum (2005) 1.08
Natural killer cells infiltrating colorectal cancer and MHC class I expression. Mol Immunol (2005) 1.08
Tumor budding as a prognostic marker in stage-III rectal carcinoma. Int J Colorectal Dis (2007) 1.05
Risk factors for occult lymph node metastasis of colorectal cancer invading the submucosa and indications for endoscopic mucosal resection. Dis Colon Rectum (2007) 1.03
Tumour budding at invasive margins and outcome in colorectal cancer. Colorectal Dis (2008) 1.03
Budding as a useful prognostic marker in pT3 well- or moderately-differentiated rectal adenocarcinoma. J Surg Oncol (2003) 1.03
Histopathologic determinants of regional lymph node metastasis in early colorectal cancer. Cancer (2008) 1.03
Local recurrence in mismatch repair-proficient colon cancer predicted by an infiltrative tumor border and lack of CD8+ tumor-infiltrating lymphocytes. Clin Cancer Res (2008) 1.02
Newer pathologic assessment techniques for colorectal carcinoma. Clin Cancer Res (2007) 1.02
Mechanisms of tumor invasion: evidence from in vivo observations. Cancer Metastasis Rev (1985) 1.00
Tumor cell budding and laminin-5 expression in colorectal carcinoma can be modulated by the tissue micro-environment. Int J Cancer (2000) 1.00
Indications for subsequent surgery after endoscopic resection of submucosally invasive colorectal carcinomas: a prospective cohort study. Dis Colon Rectum (2009) 0.99
Lymphocyte recruitment into the tumor site is altered in patients with MSI-H colon cancer. Fam Cancer (2009) 0.98
Micropapillary component in colorectal carcinoma is associated with lymph node metastasis in T1 and T2 Stages and decreased survival time in TNM stages I and II. Am J Surg Pathol (2009) 0.98
Lymphatic vessel density at the site of deepest penetration as a predictor of lymph node metastasis in submucosal colorectal cancer. Dis Colon Rectum (2007) 0.96
Histopathological risk factors for lymph node metastasis in submucosal invasive colorectal carcinoma of pedunculated or semipedunculated type. J Clin Pathol (2006) 0.96
Prognostic value of immunohistochemical analysis of tumor budding in colorectal carcinoma. Anticancer Res (2008) 0.94
The importance of T-lymphocyte subsets on overall survival of colorectal and gastric cancer patients. Medicina (Kaunas) (2007) 0.94
Budding invasive margin and prognosis in colorectal cancer--no direct association with beta-catenin expression. Eur J Cancer (2006) 0.93
A novel classification of tumour budding in colorectal cancer based on the presence of cytoplasmic pseudo-fragments around budding foci. Histopathology (2005) 0.93
Differential prognostic significance of morphologic invasive markers in colorectal cancer: tumor budding and cytoplasmic podia. Dis Colon Rectum (2006) 0.93
Pathological predictors for lymph node metastasis in T1 colorectal cancer. Surg Today (2008) 0.93
Urokinase-type plasminogen activator is a marker of aggressive phenotype and an independent prognostic factor in mismatch repair-proficient colorectal cancer. Hum Pathol (2009) 0.90
Tumor budding is predictive of lymphatic involvement and lymph node metastases in submucosal invasive colorectal adenocarcinomas and in non-polypoid compared with polypoid growths. Scand J Gastroenterol (2009) 0.89
Coexpression of matrilysin and laminin-5 gamma2 chain may contribute to tumor cell migration in colorectal carcinomas. Dig Dis Sci (2003) 0.89
HLA-DR expression is associated with better prognosis in sporadic Australian clinicopathological Stage C colorectal cancers. Int J Cancer (2009) 0.89
Venous invasion may predict lymph node metastasis in early rectal cancer. Eur J Surg Oncol (2002) 0.89
MMP-9 and cathepsin B expression in tumor budding as an indicator of a more aggressive phenotype of colorectal cancer (CRC). Anticancer Res (2006) 0.88
Tumor border configuration added to TNM staging better stratifies stage II colorectal cancer patients into prognostic subgroups. Cancer (2009) 0.87
The "Fas counterattack" is not an active mode of tumor immune evasion in colorectal cancer with high-level microsatellite instability. Hum Pathol (2007) 0.86
Evaluation of tumor cell dissociation as a predictive marker of lymph node metastasis in submucosal invasive colorectal carcinoma. Dis Colon Rectum (2005) 0.83
Morphological observation of tumor infiltrating immunocytes in human rectal cancer. World J Gastroenterol (2006) 0.83
Tumor budding and evidence-based treatment of T2 rectal carcinomas. J Surg Oncol (2005) 0.82
Frequent EpCam protein expression in human carcinomas. Hum Pathol (2004) 4.94
Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol (2014) 3.21
Cancer classification using the Immunoscore: a worldwide task force. J Transl Med (2012) 2.88
Nonsense-mediated decay microarray analysis identifies mutations of EPHB2 in human prostate cancer. Nat Genet (2004) 2.44
Prevalence of KIT expression in human tumors. J Clin Oncol (2004) 2.40
Selecting immunohistochemical cut-off scores for novel biomarkers of progression and survival in colorectal cancer. J Clin Pathol (2006) 2.17
Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis. Int J Cancer (2010) 2.08
High frequency of tumor-infiltrating FOXP3(+) regulatory T cells predicts improved survival in mismatch repair-proficient colorectal cancer patients. Int J Cancer (2010) 1.96
Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: tumor budding as oncotarget. Oncotarget (2010) 1.88
Estrogen receptor β expression and androgen receptor phosphorylation correlate with a poor clinical outcome in hormone-naive prostate cancer and are elevated in castration-resistant disease. Endocr Relat Cancer (2013) 1.57
HER2 gene status in primary breast cancers and matched distant metastases. Breast Cancer Res (2007) 1.45
Is the improved prognosis of p16 positive oropharyngeal squamous cell carcinoma dependent of the treatment modality? Int J Cancer (2010) 1.41
Proposal for a 10-high-power-fields scoring method for the assessment of tumor budding in colorectal cancer. Mod Pathol (2012) 1.38
Prognostic immunophenotypic biomarker studies in diffuse large B cell lymphoma with special emphasis on rational determination of cut-off scores. Leuk Lymphoma (2010) 1.34
The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment. J Transl Med (2013) 1.31
Differential diagnostic and functional role of the multi-marker phenotype CDX2/CK20/CK7 in colorectal cancer stratified by mismatch repair status. Mod Pathol (2008) 1.30
ATG5 is induced by DNA-damaging agents and promotes mitotic catastrophe independent of autophagy. Nat Commun (2013) 1.27
Prognostic significance of CD8+ T lymphocytes in breast cancer depends upon both oestrogen receptor status and histological grade. Histopathology (2011) 1.26
Comprehensive analysis of CpG island methylator phenotype (CIMP)-high, -low, and -negative colorectal cancers based on protein marker expression and molecular features. J Pathol (2011) 1.24
Node-negative colorectal cancer at high risk of distant metastasis identified by combined analysis of lymph node status, vascular invasion, and Raf-1 kinase inhibitor protein expression. Clin Cancer Res (2008) 1.23
Loss of raf-1 kinase inhibitor protein expression is associated with tumor progression and metastasis in colorectal cancer. Am J Clin Pathol (2007) 1.22
Loss of the CBX7 protein expression correlates with a more aggressive phenotype in pancreatic cancer. Eur J Cancer (2010) 1.21
Systematic analysis of proteins from different signaling pathways in the tumor center and the invasive front of colorectal cancer. Hum Pathol (2011) 1.18
Tumor infiltration by FcγRIII (CD16)+ myeloid cells is associated with improved survival in patients with colorectal carcinoma. Int J Cancer (2010) 1.16
Combined analysis of specific KRAS mutation, BRAF and microsatellite instability identifies prognostic subgroups of sporadic and hereditary colorectal cancer. Int J Cancer (2010) 1.16
The loss of the CBX7 gene expression represents an adverse prognostic marker for survival of colon carcinoma patients. Eur J Cancer (2010) 1.15
Prognostic significance of mammalian sterile20-like kinase 1 in colorectal cancer. Mod Pathol (2007) 1.13
Multimarker phenotype predicts adverse survival in patients with lymph node-negative colorectal cancer. Cancer (2008) 1.12
HMGA1 and HMGA2 protein expression correlates with advanced tumour grade and lymph node metastasis in pancreatic adenocarcinoma. Histopathology (2012) 1.11
Differential significance of tumour infiltrating lymphocytes in sporadic mismatch repair deficient versus proficient colorectal cancers: a potential role for dysregulation of the transforming growth factor-beta pathway. Eur J Cancer (2007) 1.10
Tumor budding score based on 10 high-power fields is a promising basis for a standardized prognostic scoring system in stage II colorectal cancer. Hum Pathol (2012) 1.10
Diagnostic reproducibility of tumour budding in colorectal cancer: a multicentre, multinational study using virtual microscopy. Histopathology (2012) 1.05
Next-generation tissue microarray (ngTMA) increases the quality of biomarker studies: an example using CD3, CD8, and CD45RO in the tumor microenvironment of six different solid tumor types. J Transl Med (2013) 1.04
Close association between HER-2 amplification and overexpression in human tumors of non-breast origin. Mod Pathol (2007) 1.04
RHAMM, p21 combined phenotype identifies microsatellite instability-high colorectal cancers with a highly adverse prognosis. Clin Cancer Res (2008) 1.04
Expression of B-cell markers in classical hodgkin lymphoma: a tissue microarray analysis of 330 cases. Mod Pathol (2003) 1.03
HOX D13 expression across 79 tumor tissue types. Int J Cancer (2009) 1.02
Local recurrence in mismatch repair-proficient colon cancer predicted by an infiltrative tumor border and lack of CD8+ tumor-infiltrating lymphocytes. Clin Cancer Res (2008) 1.02
Possible role of Cdx2 in the serrated pathway of colorectal cancer characterized by BRAF mutation, high-level CpG Island methylator phenotype and mismatch repair-deficiency. Int J Cancer (2013) 1.02
Differential pattern and prognostic significance of CD4+, FOXP3+ and IL-17+ tumor infiltrating lymphocytes in ductal and lobular breast cancers. BMC Cancer (2012) 1.01
Overexpression of the receptor for hyaluronic acid mediated motility is an independent adverse prognostic factor in colorectal cancer. Mod Pathol (2006) 1.01
Scoring of p53, VEGF, Bcl-2 and APAF-1 immunohistochemistry and interobserver reliability in colorectal cancer. Mod Pathol (2006) 1.01
Tumour growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with small-volume or low-grade prostate cancer. Int J Cancer (2009) 1.00
The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of nonmuscle-invasive bladder cancer after intravesical Bacillus Calmette-Guérin therapy. Int J Cancer (2009) 1.00
Patterns of gene amplification in gastrointestinal stromal tumors (GIST). Lab Invest (2005) 0.99
High myeloperoxidase positive cell infiltration in colorectal cancer is an independent favorable prognostic factor. PLoS One (2013) 0.97
Intra-tumoral budding in preoperative biopsy specimens predicts lymph node and distant metastasis in patients with colorectal cancer. Mod Pathol (2012) 0.97
Characterization of the immunological microenvironment of tumour buds and its impact on prognosis in mismatch repair-proficient and -deficient colorectal cancers. Histopathology (2011) 0.97
Loss of APAF-1 expression is associated with tumour progression and adverse prognosis in colorectal cancer. Eur J Cancer (2007) 0.96
Intratumoral budding as a potential parameter of tumor progression in mismatch repair-proficient and mismatch repair-deficient colorectal cancer patients. Hum Pathol (2011) 0.95
Systematic assessment of the prognostic impact of membranous CD44v6 protein expression in colorectal cancer. Histopathology (2009) 0.95
TIA-1 cytotoxic granule-associated RNA binding protein improves the prognostic performance of CD8 in mismatch repair-proficient colorectal cancer. PLoS One (2010) 0.95
Effect of EpCAM, CD44, CD133 and CD166 expression on patient survival in tumours of the ampulla of Vater. J Clin Pathol (2011) 0.95
Deletion of the inhibitor of growth 4 (ING4) tumor suppressor gene is prevalent in human epidermal growth factor 2 (HER2)-positive breast cancer. Hum Pathol (2011) 0.94
Role of KCNMA1 in breast cancer. PLoS One (2012) 0.94
Klf4 transcription factor is expressed in the cytoplasm of prostate cancer cells. Eur J Cancer (2012) 0.94
The apoptotic and proliferation rate of tumour budding cells in colorectal cancer outlines a heterogeneous population of cells with various impacts on clinical outcome. Histopathology (2013) 0.94
High tumor budding stratifies breast cancer with metastatic properties. Breast Cancer Res Treat (2015) 0.94
The impact of CpG island methylator phenotype and microsatellite instability on tumour budding in colorectal cancer. Histopathology (2012) 0.94
Co-overexpression of p21 and Ki-67 in head and neck squamous cell carcinoma relative to a significantly poor prognosis. Head Neck (2011) 0.93
Tumor budding predicts response to anti-EGFR therapies in metastatic colorectal cancer patients. World J Gastroenterol (2010) 0.93
CD8/CD45RO T-cell infiltration in endoscopic biopsies of colorectal cancer predicts nodal metastasis and survival. J Transl Med (2014) 0.93
ABCG5-positivity in tumor buds is an indicator of poor prognosis in node-negative colorectal cancer patients. World J Gastroenterol (2010) 0.91
Value of staining intensity in the interpretation of immunohistochemistry for tumor markers in colorectal cancer. Virchows Arch (2007) 0.91
High CD10 expression in lymph node metastases from surgically treated prostate cancer independently predicts early death. Virchows Arch (2011) 0.90
Urokinase-type plasminogen activator is a marker of aggressive phenotype and an independent prognostic factor in mismatch repair-proficient colorectal cancer. Hum Pathol (2009) 0.90
Systematic assessment of protein phenotypes characterizing high-grade tumour budding in mismatch repair-proficient colorectal cancer. Histopathology (2010) 0.90
High-level cytoplasmic cyclin D1 expression in lymph node metastases from prostate cancer independently predicts early biochemical failure and death in surgically treated patients. Histopathology (2011) 0.89
High-throughput tissue microarray analysis of G1-cyclin alterations in classical Hodgkin's lymphoma indicates overexpression of cyclin E1. J Pathol (2003) 0.88
Tumor budding in colorectal cancer revisited: results of a multicenter interobserver study. Virchows Arch (2015) 0.88
Clinical significance of cell cycle- and apoptosis-related markers in biliary tract cancer: a tissue microarray-based approach revealing a distinctive immunophenotype for intrahepatic and extrahepatic cholangiocarcinomas. Am J Clin Pathol (2008) 0.88
The growing galectin network in colon cancer and clinical relevance of cytoplasmic galectin-3 reactivity. Anticancer Res (2013) 0.88
Characterization of CDKN2A(p16) methylation and impact in colorectal cancer: systematic analysis using pyrosequencing. J Transl Med (2012) 0.88